加巴喷丁在复发性三叉神经痛治疗中的临床应用  

Clinical application of gabapentin in the treatment of recurrent trigeminal neuralgia

作　　者：庞啸虎[1] 吴秀玮 高丽[1] 

机构地区：[1]徐州市第一人民医院神经内科,江苏省徐州221002

出　　处：《中国基层医药》2017年第23期3544-3548,共5页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的 探讨加巴喷丁在复发性三叉神经痛治疗中的临床应用效果.方法 选取复发性三叉神经痛患者68例为研究对象,采用随机数字表法将其分为研究组与对照组,研究组给予加巴喷丁治疗,对照组给予卡马西平治疗,治疗4周后比较两组患者临床疗效、生活满意度、疼痛程度、药物剂量及不良反应发生情况.结果 两组各有32例患者完成研究.研究组总有效率高于对照组（68.75％比59.37％）,但差异无统计学意义（x^2 =0.611,P＜0.05）.研究组加巴喷丁平均剂量为（1 732.65±532.17） mg/d,对照组卡马西平平均剂量为（642.98±124.53） mg/d,两组药物剂量差异有统计学意义（t=11.278,P＜0.05）.治疗前两组患者疼痛视觉模拟评分（VAS评分）差异无统计学意义（t=0.153,P＞0.05）,治疗7d时研究组VAS评分较对照组低[（4.09±0.83）分比（4.63±0.79）分],差异有统计学意义（t=2.666,P＜0.05）;治疗14 d及28 d时两组患者VAS评分差异均无统计学意义（t=1.527、0.352,均P＞0.05）.治疗前及治疗7d时两组患者生活满意度指数B（LSI-B）评分差异均无统计学意义（t=0.049、0.224,均P＞0.05）,治疗14 d及28 d时两组患者LSI-B评分均明显增高,研究组LSI-B评分较对照组高[14 d：（15.09±3.68）分比（12.91 ±3.45）分,28 d：（16.48±3.43）分比（13.35±3.14）分],差异均有统计学意义（t=2.445、3.808,均P＜0.05）.研究组不良反应发生率较对照组低（15.63％比37.50％）,差异有统计学意义（x^2=3.925,P＜0.05）.结论 加巴喷丁与卡马西平均对复发性三叉神经痛有着良好疗效,但加巴喷丁可更好改善患者生活质量,安全性更佳.Objective To investigate the clinical application effects of gabapentin in the treatment of recurrent trigeminal neuralgia.Methods 68 patients with recurrent trigeminal neuralgia were chosen as study subjects,and they were divided into control group and research group according to the digital table.The research group was treated with gabapentin,the control group was treated with carbamazepine.After treatment for 4 weeks,the clinical effects,life satisfactory index,pain,drug dosage and adverse reaction between the two group were compared.Results Each group had 32 patients completed the study.The total effective rate of the research group was higher than that of the control group（68.75% vs.59.37%）,the difference was not statistically significant（x^2 =0.611,P 〈0.05）.The average gabapentin dosage in the research group was higher than the average carbamazepine dosage in the control group,the difference was statistically significant （t =11.278,P 〈 0.05）.Before treatment,the VAS scores between the two groups had no statistically significant difference （t =0.153,P 〉 0.05）.At 7 d after treatment,the VAS scores in the research group was lower than that in the control group [（4.09 ± 0.83） points vs.（4.63 ± 0.79） points],the difference was statistically significant （t =2.666,P 〈 0.05）.At 14 d and 28 d after treatment,the VAS scores between the two groups had no statistically significant difference （t =1.527,0.352,all P 〉 0.05）.Before treatment and 7 d after treatment,the life satisfaction index B （LSI-B） scores between the two groups had no statistically significant difference（t =0.049,0.224,all P 〉 0.05）.At 14 d and 28 d after treatment,LSI-B scores in the two groups were both increased,which in the research group was higher than taht in the control group[14 d：（15.09 ± 3.68） points vs.（12.91 ± 3.45） points,28 d：（16.48 ± 3.43） points vs.（13.35 ± 3.14） points],the differences were statistically different（t =2.445,3.808,all P 〈 0.05）.The incide

关 键 词：三叉神经痛 加巴喷丁 卡马西平 

分 类 号：R745.11[医药卫生—神经病学与精神病学]